Latest Dermatology News

Page 1 of 6
Mayne Pharma has agreed to a A$6.40-a-share cash takeover by Hungary’s Gedeon Richter, valuing the company’s equity at approximately A$604 million. The recommended scheme still depends on regulatory clearances, shareholder and court approval, and completion of Mayne’s international business sale.
Victor Sage
Victor Sage
17 Nov 2026
Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
Victor Sage
6 Nov 2026
Zoetis lifted its full-year adjusted earnings outlook after a mixed third quarter, but US companion animal revenue fell 8% amid price sensitivity, competition and generic pressure. The animal health group also reported an 18% drop in GAAP net income and a US$89 million impairment charge.
Ada Torres
Ada Torres
5 Nov 2026
Mayne Pharma’s unaudited first-quarter revenue fell 2% to A$95.7 million, while underlying EBITDA dropped 52% as generic competition hit Dermatology. Strong prescription growth in Women’s Health and DistributeRx offered a partial counterweight, alongside progress on key legal disputes.
Victor Sage
Victor Sage
26 Oct 2026
Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.
Ada Torres
Ada Torres
27 Aug 2026
Clinuvel Pharmaceuticals targets year-end for topline results from its pivotal vitiligo trial of SCENESSE® combined with narrowband UVB, aiming to expand the drug's use beyond its current rare disease indication.
Ada Torres
Ada Torres
28 July 2026
Marlin Global's portfolio delivered a 2.0% gross return in Q2 2026, driven by rebounds in ICON and semiconductor holdings, but lagged a strong US market rally led by AI and chip stocks.
Victor Sage
Victor Sage
20 July 2026
Marlin Global’s portfolio lagged the broader market in May 2026, weighed down by semiconductor underexposure and near-term revenue challenges in key holdings, while AI-focused stocks powered a narrow rally.
Claire Turing
Claire Turing
12 June 2026
Mayne Pharma has received $14.4 million from Cosette Pharmaceuticals covering legal costs and interest following a Supreme Court ruling in its favour. The legal battle continues with Cosette’s appeal decision pending.
Victor Sage
Victor Sage
5 June 2026
Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.
Ada Torres
Ada Torres
29 Apr 2026
Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.
Ada Torres
Ada Torres
29 Apr 2026
CLINUVEL Pharmaceuticals has received final scientific advice from the European Medicines Agency on the design of its pivotal Phase III trial for SCENESSE in vitiligo, endorsing a comprehensive evidence approach and prioritising patients with darker skin tones.
Ada Torres
Ada Torres
24 Apr 2026

Browse the archive

Full archive